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Abstract This study was performed to determine the involve-
ment of type II phospholipase A2 (PLA2-II) in renal injury
caused by ischemia and reperfusion. Ischemia and reperfusion
significantly elevated levels of blood urea nitrogen and serum
creatinine in rats. These increases were significantly reduced by
i.v. administration of rabbit IgG F(abP)2 fragments against rat
PLA2-II. Increased levels of acid-stable PLA2 activity in the
kidney were caused by ischemia and reperfusion, and were
suppressed by administration of anti-PLA2-II F(abP)2. Increased
levels of myeloperoxidase activity, a marker of neutrophil
infiltration, in the kidney were also reduced after anti-PLA2-II
F(abP)2 treatment. These results suggest that PLA2-II plays a
pivotal role in pathogenesis of ischemia and reperfusion injury
through induction of neutrophil infiltration.
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1. Introduction
Phospholipase A2 (PLA2), which hydrolyzes the sn-2 ester
bonds of phospholipids to yield free fatty acids and lysophos-
pholipids, is not only involved in lipid metabolism but is crit-
ical to signal transduction and production of proin£ammatory
lipid mediators [1]. Three types of Ca2-dependent PLA2,
types I, II and IV, have been identi¢ed in rat kidney tissue
[2,3]. Types I and II are 14 kDa proteins, secreted from var-
ious cells such as macrophages, endothelial cells, renal mesan-
gial cells, and ¢broblasts, and exhibit no speci¢city for the
fatty acid at the sn-2 position of phospholipids [1]. Type IV
PLA2 is an 85 kDa protein, ubiquitously expressed in cytosol,
which exhibits a preference for arachidonic acid at sn-2. Type
I PLA2 is localized in pancreatic juice and its main role is
digestion of phospholipids in food. Type II PLA2 (PLA2-II)
has been detected in a wide variety of in£ammatory patients,
such as rheumatoid arthritis, septic shock, and pancreatitis,
and is therefore implicated in the in£ammation process [4].
Neutrophil in¢ltration during ischemia and reperfusion has
been implicated as a key mediator in renal tissue injury
through release of oxygen radicals, proteases, arachidonic
acid metabolites and other cytotoxic species [5]. On the other
hand, Ca2-dependent, low molecular PLA2 activity increases
in experimental models of kidney ischemia [6,7]. In connection
with those ¢ndings, PLA2-II exogenous added to cell culture
media activates CD11b/CD18 expression, degranulations,
superoxide production and generation of arachidonic acid me-
tabolites in neutrophils [2,8^11]. From those observations, it is
surmised that PLA2-II plays a critical role in renal injury due
to ischemia and reperfusion through neutrophil activation.
In the present study, the involvement of PLA2-II in acute
renal failure was evaluated by the e¡ects of antibodies against
PLA2-II on renal injury due to ischemia and reperfusion in
rats.
2. Materials and methods
2.1. Preparation of F(abP)2 fragments of rabbit IgG against
rat PLA2-II
Platelets from about 100 Wistar rats (body weight 400^500 g) were
stimulated with thrombin, and PLA2-II was puri¢ed as described by
Horigome et al. [12]. The puri¢ed protein gave a single protein band
on SDS-PAGE, the molecular mass of which was estimated to be 14
kDa, corresponding to rat PLA2-II.
F(abP)2 fragments of rabbit IgG against rat PLA2-II (anti-PLA2-II
F(abP)2) were prepared as described elsewhere [10]. Brie£y, rabbits
(KBL:JW) were immunized 4 times with 0.1 mg of puri¢ed rat
PLA2-II emulsi¢ed in Freund’s complete adjuvant. The serum IgG
was puri¢ed with protein A-Sepharose column (Pharmacia LKB Bio-
technology, Piscataway, NJ) and digested with pepsin. The F(abP)2
fragment was puri¢ed by Sephacryl S-200HR gel ¢ltration column
(Pharmacia). The F(abP)2 solution was adjusted to 1 mg/ml in saline.
Non-immune F(abP)2 was prepared from normal rabbit serum by the
same way.
2.2. Surgical procedures
Male Wistar rats (body weight about 300 g, Japan SLC, Hamamat-
su) were used in the following experiments, which were performed in
accordance with the regulations of the Animal Ethical Committee of
Yamanouchi Pharmaceutical Co. Ltd. The rats were anesthetized with
pentobarbital sodium (50 mg/kg, i.p.) and the body temperature was
maintained at 37‡C with a warming pad. A jugular venous catheter
was inserted in all animals for drug administration and blood sam-
pling. Both kidneys were exposed, and the renal arteries and veins
were occluded bilaterally for 60 min with non-traumatic vascular
clamps. Reperfusion was initiated by removing the clamps, and the
abdomen was closed.
Sham-operated control animals (eight rats) without renal ischemia
formed group I. The rats with renal ischemia were divided into three
groups. Groups II, III, and IV were given saline, non-immune F(abP)2
and anti-PLA2-II F(abP)2, respectively. Non-immune F(abP)2 or anti-
PLA2-II F(abP)2 was i.v. administered in a bolus dose of 5 mg/5 ml
saline/kg at the time of reperfusion, followed by i.v. infusion at a rate
of 5 mg/5 ml saline/kg/h for the subsequent 6 h. This dosage was
based on the following experiments. Pharmacokinetic analysis esti-
mated the half-life of F(abP)2 in rats to be 11 h. This bolus plus
infusion dosage yielded a concentration of 200 Wg/ml in plasma and
provided a concentration of s 10 Wg/ml during the in vivo experimen-
tal period (48 h), whereas 100% inhibition of PLA2-II was achieved in
vitro (Fig. 1).
Venous blood was drawn from the jugular vein 48 h after reperfu-
sion. Levels of blood urea nitrogen (BUN) and serum creatinine of
those samples were measured with diagnostic kits (BUN Test Wako
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and Creatinine Test Wako; Wako Pure Chemical Co. Ltd., Osaka,
Japan).
Animals were killed 48 h after reperfusion, and both kidneys were
excised. The left kidneys were ¢xed in formalin and stained with
hematoxylin and eosin. The right kidneys were stored at 380‡C for
measurement of PLA2 and myeloperoxidase activities as described
below.
2.3. Assay of PLA2 and myeloperoxidase (MPO) activities
Kidneys were homogenized in 10 ml of 10 mM Tris-HCl (pH 7.4)
containing 1 mM EDTA with a Potter-type homogenizer. For meas-
urement of PLA2 activity, 5 ml of kidney homogenate was extracted
with 0.18 N H2SO4 on ice for 60 min as described by Maºrki and
Franson [13]. The extracts were centrifuged at 15 000 rpm at 4‡C
for 30 min. The supernatants were dialyzed against 50 mM Tris-
HCl (pH 7.4) containing 0.2 M NaCl. PLA2 activities in the acid
extracts were measured using [3H]oleic acid labeled, autoclaved Es-
cherichia coli as substrate, as described previously [10].
For measurement of MPO activity, 5 ml of kidney homogenate
were extracted in 50 mM phosphate bu¡er (pH 6.0) containing
0.5% hexadecyltrimethylammonium bromide, and the MPO activities
in the extracts were measured using tetramethylbenzidine as substrate
as described by Laight et al. [14].
Protein concentrations of kidney extracts were assessed with the
Protein Assay Kit (Bio-Rad Laboratories, Richmond, CA).
2.4. Statistical analysis
All data are indicated as the means þ S.E.M. Statistical analysis was
performed by Student’s t-test for comparisons between two groups.
3. Results
3.1. Speci¢city of rabbit anti-PLA2-II F(abP)2
I.v. administration of anti-PLA2-II IgG, but not its F(abP)2
fragment, greatly decreased platelets in rats (data not shown),
which may be due to e¡ector functions of the Fc moiety of
IgG. Therefore, the F(abP)2 fragment but not the whole IgG
molecule was used for in vivo studies.
Speci¢city and binding capacity of anti-PLA2-II F(abP)2
were investigated by ELISA using plates coated with rat
PLA2-II or porcine PLA2-I (Fig. 1A). Anti-PLA2-II F(abP)2
bound to PLA2-II but not to PLA2-I. To determine the e¡ect
on the PLA2 activity, anti-PLA2-II F(abP)2 or non-immune
F(abP)2 were pre-incubated with rat PLA2-II or porcine
PLA2-I at room temperature for 60 min. Residual enzyme
activities were measured with [3H]oleic acid labeled, auto-
claved E. coli as substrate (Fig. 1B). Anti-PLA2-II F(abP)2
inhibited the enzyme activity of PLA2-II but not PLA2-I,
while non-immune F(abP)2 did not inhibit either PLA2-II or
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Fig. 1. Speci¢city of anti-PLA2-II F(abP)2. A: Binding capacity was
investigated by ELISA assay using plates coated with 5 ng/well of
rat PLA2-II (F) or porcine PLA2-I (b). B: Anti-PLA2-II F(abP)2
(closed symbols) or non-immune F(abP)2 (open symbols) was incu-
bated with 0.5 ng of rat PLA2-II (F,E) or porcine PLA2-I (b,a).
Residual PLA2 activities are expressed as percentages of control not
treated with any F(abP)2.
Fig. 2. E¡ects of anti-PLA2-II F(abP)2 on rat renal functions 48 h
after ischemia and reperfusion. Levels of BUN and serum creatinine
were measured in the blood samples of the sham-operated control
animals (n = 8), saline, non-immune F(abP)2- and anti-PLA2-II
F(abP)2-treated rats (n = 10) with ischemia and reperfusion. Closed
bars represent BUN levels and open bars represent serum creatinine
levels. Those levels are expressed as means þ S.E.M. **P6 0.01.
J. Takasaki et al./FEBS Letters 440 (1998) 377^381378
PLA2-I. Thus, the rabbit anti-PLA2-II F(abP)2 used here
blocks the enzyme activity of PLA2-II with high speci¢city.
3.2. E¡ect of anti-PLA2-II F(abP)2 on rat renal injury due to
ischemia and reperfusion
The renal arteries and veins of rats were occluded bilaterally
with clamps for 60 min and the kidneys were then reperfused
by removing the clamps. The levels of BUN and serum crea-
tinine were assessed 48 h after ischemia and reperfusion (Fig.
2). The BUN values in saline-treated animals with ischemia
and reperfusion (group II) was 50.0 þ 9.4 mg/dl vs. 15.0 þ 2.0
mg/dl (P6 0.01) in sham-operated animals (group I). The
creatinine values in group II was 0.75 þ 0.05 mg/dl vs.
0.30 þ 0.02 mg/dl (P6 0.01) in group I. Ischemia and reperfu-
sion signi¢cantly elevated BUN and serum creatinine 48 h
after reperfusion, implying acute renal failure. The i.v. admin-
istration of non-immune F(abP)2 (group III) had no e¡ect on
increases of either marker. Treatment with anti-PLA2-II
F(abP)2 (group IV) signi¢cantly reduced the increase of both
BUN and serum creatinine compared with the non-immune
F(abP)2-treated group (Fig. 2; BUN values: 26.4 þ 3.5 mg/dl
vs. 48.0 þ 8.2 mg/dl (P6 0.01); creatinine values: 0.52 þ 0.02
mg/dl vs. 0.73 þ 0.04 mg/dl (P6 0.01)). Therefore, it is highly
likely that PLA2-II is involved in injury due to ischemia and
reperfusion in kidneys.
Kidneys excised after 48 h were examined histologically by
staining with hematoxylin and eosin (data not shown). Non-
immune F(abP)2-treated animals showed severe tubular ne-
crosis, while the tubules remained fairly intact in anti-PLA2-
II F(abP)2-treated animals. These ¢ndings were consistent
with results of BUN and serum creatinine level experiments.
3.3. PLA2 activity in the kidney
PLA2 activity was assessed to see if the enzyme activity in
the kidney was suppressed by administration of anti-PLA2-II
F(abP)2 (Fig. 3A). PLA2 activity of the kidney extracts in
saline-treated animals with ischemia and reperfusion (group
II) was 0.45 þ 0.04 nmol/min/mg vs. 0.29 þ 0.02 nmol/min/mg
(P6 0.01) in sham-operated animals (group I). PLA2 activity
in kidney extracts signi¢cantly increased 48 h after ischemia
and reperfusion. The elevation of PLA2 activity after ischemia
was cancelled by pre-incubation with anti-PLA2-II F(abP)2
(100 Wg/ml) in vitro (Fig. 3B). Thus, the major part of the
increase was due to PLA2-II enzyme. Treatment with non-
immune F(abP)2 (group III) had no e¡ect on kidney PLA2
activity. Treatment with anti-PLA2-II F(abP)2 (group IV) sig-
ni¢cantly reduced the increase of kidney PLA2 activity com-
pared with non-immune F(abP)2-treated animals (Fig. 3A;
0.26 þ 0.02 nmol/min/mg vs. 0.50 þ 0.06 nmol/min/mg
(P6 0.01)). Therefore, the increase of PLA2 activity caused
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Fig. 3. PLA2 activity in the kidneys 48 h after ischemia and reperfu-
sion. A: PLA2 activity of the kidney acid extracts are expressed as
means þ S.E.M. (n = 10). **P6 0.01. B: PLA2 activity of the kidney
extracts of sham-operated control rats and saline-treated rats with
ischemia and reperfusion, which were pre-incubated without (closed
bars) or with (open bars) 100 Wg/ml anti-PLA2-II F(abP)2 (n = 5).
Fig. 4. MPO activity in the kidneys 48 h after ischemia and reperfu-
sion. MPO activity of the kidney extracts is expressed as means
þ S.E.M.(n = 10). *P6 0.05, **P6 0.01.
J. Takasaki et al./FEBS Letters 440 (1998) 377^381 379
by PLA2-II enzyme in kidney after ischemia and reperfusion
injury was inhibited by administration of anti-PLA2-II
F(abP)2.
3.4. MPO activity in the kidney
Neutrophil in¢ltration during ischemia and reperfusion has
been implicated as a key mediator in renal tissue injury. But
in¢ltration of neutrophils in kidney is not a prominent feature
of human ischemic acute renal failure or experimental acute
renal failure when tissue is assessed using routine histologic
stains [15,16]. In contrast, assays for neutrophil-derived en-
zymes, such as MPO, reveal a robust neutrophil existence in
ischemic kidney [14,18]. In this experiment, MPO activities in
the kidney were measured as a marker of neutrophil in¢ltra-
tion (Fig. 4). The enzyme activities in saline-treated animals
with ischemia and reperfusion (group II) was 0.23 þ 0.01 U/g
vs. 0.15 þ 0.01 U/g (P6 0.01) in sham-operated animals
(group I), suggesting that neutrophils in¢ltrated into kidney
tissue damaged by ischemia and reperfusion. Treatment with
non-immune F(abP)2 (group III) had no e¡ect on kidney
MPO activity. The increase of kidney MPO activity was sig-
ni¢cantly reduced in anti-PLA2-II F(abP)2-treated animals
(group IV) compared with non-immune F(abP)2-treated ani-
mals (Fig. 4; 0.17 þ 0.01 U/g vs. 0.23 þ 0.01 U/g (P6 0.05)).
These results suggest that neutrophils in¢ltrate into damaged
kidney tissue and that PLA2-II is involved in the neutrophil
in¢ltration process.
4. Discussion
The present study demonstrated that administration of anti-
PLA2-II F(abP)2 prevents increases in BUN and serum crea-
tinine, which are indicators of glomerular ¢ltration rate dys-
function caused by tubular necrosis, after ischemia and reper-
fusion injury.
Types I, II and IV have been identi¢ed in rat kidney tissue
[2,3]. Anti-PLA2-II F(abP)2 is capable of totally inhibiting
type II PLA2 but not type I. Since 100 kDa F(abP)2 does
not penetrate the cell membrane, it is not possible for anti-
PLA2-II F(abP)2 to inhibit cytosolic PLA2 (PLA2-IV) in vivo.
The protective e¡ect of anti-PLA2-II F(abP)2 on renal injury
due to ischemia and reperfusion would result from inhibition
of type II PLA2 but not inhibition of either type I or IV.
To assess the PLA2 activities in the kidney in this study, the
enzyme was extracted from the kidney with acid because type
II is resistant to low pH unlike types I and IV [13,18]. PLA2
activities of acid extracts were signi¢cantly elevated 48 h after
ischemia and reperfusion and the elevation was inhibited by
administration of anti-PLA2-II F(abP)2. It is con¢rmed that
the elevation was also inhibited by addition of exogenous
anti-PLA2-II F(abP)2 in vitro. Thus, the elevated PLA2 activ-
ities appear to be due to an increase of type II enzyme. Na-
kamura and his co-workers [6] previously showed that renal
ischemia and reperfusion resulted in an increase of PLA2 ac-
tivity associated with a soluble 14 kDa protein. Also, exposure
of rat renal proximal tubules to hypoxia resulted in activation
of a Ca2-dependent 15 kDa PLA2 and its release out of cells
[7]. However, they did not determine whether it was PLA2-II
or other types. The present study has revealed for the ¢rst
time that renal ischemia and reperfusion injury induces acti-
vation of PLA2-II in the kidney and that inhibition of the
enzyme reduces renal tissue damage.
The ¢nding that anti-PLA2-II F(abP)2 reduced MPO activ-
ity in renal ischemia and reperfusion suggests that the protec-
tive e¡ect of anti-PLA2-II F(abP)2 results from suppression of
neutrophil in¢ltration. In renal ischemia and reperfusion in-
jury, neutrophils mediate tissue injury through release of oxy-
gen radicals, proteases, arachidonic acid metabolites and oth-
er cytotoxic species [5,19]. Neutrophil in¢ltration in kidney
tissue after ischemia and reperfusion is regulated by interac-
tion of the neutrophil CD11a/b with intercellular adhesion
molecule 1 (ICAM-1) of endothelial cells [16,17,20]. It was
showed that PLA2-II induces expression of Mac-1 (CD11b/
CD18) on human neutrophils through free fatty acid produc-
tion [10]. PLA2-II also induces expression of ICAM-1 on en-
dothelial cells through lysophospholipid production [21]. In
addition, it is suggested that the increase in free fatty acids
and lysophospholipids after ischemia and reperfusion is corre-
lated with the increase in Ca2-dependent, low molecular
PLA2 activity [6,7]. Thus, neutrophil in¢ltration may be in-
duced by the degradation products of phospholipids, which is
produced by PLA2-II. Systemic levels of tumor necrosis factor
K (TNF-K) and interleukin 1 (IL1), two cytokines known to
induce PLA2-II expression [1,4], is elevated after renal ische-
mia and reperfusion [19]. TNF-K and IL1 also up-regulate
Mac-1 surface expression [22], and PLA2-II and cytokines
have synergistic e¡ect on Mac-1 surface expression [11], thus
PLA2-II induced by cytokines may augment cytokine-induced
neutrophil activation by positive feedback. These ¢ndings sug-
gest that PLA2-II induced by ischemia and reperfusion di-
rectly and/or indirectly modulates the activation of neutro-
phils, which in¢ltrate into the kidney and produce cytotoxic
substances leading to tissue injury.
In contrast to the ¢ndings described above, PLA2-I had a
cytoprotective e¡ect on isolated rat proximal tubules which
were subjected to hypoxia and reoxygenation, even though
the concentrations of free fatty acids were increased by the
addition of PLA2-I [23]. There has been no evidence of such a
cytoprotective e¡ect with PLA2-II. Our ¢nding in renal ische-
mia and reperfusion with PLA2-II-speci¢c antibodies supports
the thesis that type II enzyme works in vivo as a pathogenic
factor rather than a protective factor.
Since anti-PLA2-II F(abP)2 ameliorated acute renal failure
caused by ischemia and reperfusion, antibodies against PLA2-
II could be a useful therapeutic tool to acute renal failure
caused by ischemia.
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